SALEM, Mass. — Commonwealth Diagnostics International (CDI) is excited to share the benefits of our new in-network status with CareFirst BlueCross BlueShield and CareFirst BlueChoice, the most extensive not-for-profit health plan in the Mid-Atlantic. This partnership, covering over 3.5 million individuals and groups in Maryland, the Washington D.C. metropolitan area, and parts of Virginia, significantly enhances…
SALEM, Mass. — Commonwealth Diagnostics International, Inc. (CDI), The Leader in Hydrogen and Methane Breath Testing®, is now in-network with Blue Cross and Blue Shield of Illinois (BCBSIL), the state’s largest health insurance company. This significant development is part of CDI’s ongoing efforts to enhance accessibility to its clinically validated non-invasive at-home breath tests for…
CDI is proud to announce the launch of our new hydrogen and methane breath test kit registration process, designed to optimize the testing experience for healthcare providers and their patients. This streamlined process ensures that patients receive personalized support, enhancing the accuracy and efficiency of test results. Here’s how it simplifies the process for your…
Dear CDI Team Members, Healthcare Partners, and Industry Stakeholders: As we reflect on our past year, we can see clearly staring back at us a period marked by growth, resilience, innovation, and impact. This year, CDI has not just navigated but thrived in a complex and evolving healthcare environment. Our dedication to enhancing the quality…
MyGI Gateway will transform hydrogen and methane breath testing with streamlined kit registration, advanced patient engagement, and analytics throughout the diagnostic process. SALEM, Mass. – October 20, 2023 – Commonwealth Diagnostics International, Inc. (CDI), The Leader In Hydrogen and Methane Breath Testing®, is excited to announce the launch of MyGI Gateway™, a cutting-edge cloud-based provider…
As the Leader in Hydrogen and Methane Breath Testing, CDI follows industry best practices and stays current with the latest industry research to provide its patients with the best test taking experience. As such, we are pleased to announce updates to all our breath test Instructions for Use (IFUs), including an expanded list of permitted…
The latest functional gastrointestinal (GI) trends are now available in the third issue of Modern Gastro presented by CDI. Featured content in the Q1 2023 issue of Modern Gastro includes: A Letter from CDI’s President & CEO Carbohydrate Malabsorption Disorders 101 Highlights from the latest CDI-hosted GI Trends Webinar SIBO Case Study Additional #GIcommunity Insights…
Dear Team Members, Healthcare Providers, Patients, and all Stakeholders of CDI: You are valued and appreciated. This is the first and most important message I want to send. As I reflect on 2022 and look ahead to 2023, I’m deeply grateful for the diverse group of partners working together to ensure the collective health of…
CDI’s President & CEO Craig Strasnick was recently interviewed for The Root Cause Medicine Podcast. During the episode, Strasnick discusses small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) and how the diagnostic side of GI disturbances provides important data that helps guide research and the development of therapies to help patients find relief.…
Collaboration will accelerate and streamline gastroenterology (GI) clinical trials with an end-to-end platform for patient recruitment, enrollment, and management Salem, Mass. and Fremont, Calif. – October 20, 2022 – My Total Health Inc., in partnership with Commonwealth Diagnostics International, Inc. (CDI), announced today a strategic partnership with CliniOps in which the companies will collaborate…
